Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Practolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 4/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 5/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | CNR1 | P21554 | 1/20 | 0.62 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.62 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Practolol SCHEMBL6509191 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| Practolol SCHEMBL39925 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| Practolol SCHEMBL9117980 | 0.99 | ADRB2 (0.97) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| SCHEMBL11884649 | 0.96 | ADRB2 (0.92) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| SCHEMBL14307663 | 0.88 | ADRB2 (0.78) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| SCHEMBL21793189 | 0.86 | ADRB2 (0.76) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| SCHEMBL11640326 | 0.86 | ADRB2 (0.76) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL31148312 | 0.86 | ADRB2 (0.76) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| SCHEMBL11078398 | 0.86 | ADRB3 (0.75) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| Practolol SCHEMBL11383487 | 0.86 | ADRB2 (0.73) | ADRB2ADRB1ADRB3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4594 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213647-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA | 2025-07-03 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119233997-A | Tetrahedral antibodies | 生物分子控股有限责任公司 | 2024-12-31 | — | — | CN | claimed |
| EP-4463485-A2 | TETRAHEDRAL ANTIBODIES | Biomolecular Holdings LLC (US) | 2024-11-20 | — | — | EP | claimed |
| US-20240335390-A9 | PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS SOLID DISPERSIONS AND METHODS OF PREPARATION THEREOF | SHENZHEN PHARMACIN CO LTD (CN) | 2024-10-10 | — | — | US | claimed |
| US-20240301022-A1 | GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF | UNIV ASTON (GB) | 2024-09-12 | — | — | US | claimed |
| WO-2024102883-A1 | METHODS OF TREATING, AMELIORATING, AND/OR PREVENTING STRESS-RELATED DISORDER | YALE UNIVERSITY (US) | 2024-05-16 | — | — | WO | claimed |
| US-20240148731-A1 | PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS SOLID DISPERSIONS AND METHODS OF PREPARATION THEREOF | Shenzhen Pharmacin Co., Ltd. (CN) | 2024-05-09 | — | — | US | claimed |
| WO-2023192319-A1 | CHEMOKINE RECEPTORS AND ALPHA1 ADRENERGIC RECEPTORS/VASOPRESSIN RECEPTORS 1A HETEROMERS AS DRUG TARGETS FOR DISEASE | UNIVERSITY OF SOUTH FLORIDA (US) | 2023-10-05 | — | — | WO | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| EP-0154009-A1 | Use of a thiazide diuretic for the manufacture of a non-diuretic antihypertensive medicament | Euro-Celtique S.A. (LU) | 1985-09-11 | — | — | EP | claimed |
| EP-0073819-A4 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR. | UNIV KENTUCKY RES FOUND (US) | 1984-11-16 | — | — | EP | claimed |
| EP-0105996-A1 | Ophthalmic compositions for treating elevated intraocular pressure | MERCK & CO. INC. (US) | 1984-04-25 | — | — | EP | claimed |
| US-4428883-A | NASAL OINTMENTS OR GELS | THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1984-01-31 | — | — | US | claimed |
| EP-0073819-A1 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR. | UNIV KENTUCKY RES FOUND (US) | 1983-03-16 | — | — | EP | claimed |
| WO-1982003009-A1 | NASAL ADMINISTRATION OF BETA-BLOCKERS AND DOSAGE FORMS THEREFOR | UNIV KENTUCKY RES FOUND (US) | 1982-09-16 | — | — | WO | claimed |
| US-4303637-A | Medication indicated for ocular hypertension | ALZA CORPORATION (US) | 1981-12-01 | — | — | US | claimed |
| EP-0037622-A2 | Drug delivery insert for controlled ocular therapy | ALZA CORPORATION (US) | 1981-10-14 | — | — | EP | claimed |
| US-4281654-A | Drug delivery system for controlled ocular therapy | ALZA CORPORATION (US) | 1981-08-04 | — | — | US | claimed |
| US-4256108-A | Microporous-semipermeable laminated osmotic system | ALZA CORPORATION (US) | 1981-03-17 | — | — | US | claimed |